louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01985932: Functional MRI Use in Prostate Radiation Treatment Planning
Official title: A Prospective Study Evaluating Non-Endorectal Coil Functional MRI Identification of Intraprostatic Tumor During Radiation Treatment Planning
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2013-11-18
Enrollment: 15
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is being done to evaluate the use of MRI during radiation treatment planning to identify areas of tumor within the prostate to aid in future treatment planning and targeting of prostate cancer. This study will be conducted at the University of Pennsylvania Health System. The study is projected to run for 18 months. Subjects will be male 18 or older with a prostate cancer diagnosis and treatment plansat the Department of Radiation Oncology.


Eligibility criteria: Inclusion Criteria:

* Age 18 or older
* Male
* Biopsy proven prostate cancer without evidence of metastatic disease
* Planned definitive external beam RT with daily ERB and implanted Visicoil fiducial markers.
* Prior fMRI-ec documenting an IPL 25 mm2 in axial bidimensional diameter product, concordant with intraprostatic tumor location as documented on transrectal ultrasoundbiopsy
* Subject capable of giving informed consent for standard external beam RT and for the study.
* No current contraindication that would prevent MRI or gadolinium contrast.

Exclusion Criteria:

* Metastatic disease
* Lack of fMRI-ec documeneting an IPL 25 mm2 in axial bidimensional product, concordant with intraprostatic tumor location as documented on transrectal untrasound biopsy
* Neoadjuvant androgen deprivation therapy greater than 10 weeks, defined from date of LHRH analog injection to date of fMRI-sim
* Contraindication that would prevent MRI or gadolinium contrast
* GFR 30 mL/min/1.73m2 per Crockoft-Gault formula.

Primary outcomes:
measure: Number of Participants With Adverse Events
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Curtiland Deville, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04714632: Function of Inner Ear Such as Balance and Perception of Verticality in Children With Idiopathic Scoliosis
Official title: Vestibular Function in Adolescents With Idiopathic Scoliosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Idiopathic Scoliosis
Vestibular Abnormality
Keywords: idiopathic scoliosis
subjective visual vertical
vestibular evoked myogenic potentials
posturography
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
First posted: 2021-01-19
Enrollment: 40
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children with Idiopathic scoliosis

Brief summary: The purpose of this study was to evaluate vestibular function in children with idiopathic scoliosis as a possible cause of etiopathogenesis of its diagnose.


Eligibility criteria: Inclusion Criteria:

* idiopathic scoliosis

Exclusion Criteria:

* operation of the spine
* neurological disease
* hearing problems

Primary outcomes:
measure: Vestibular evoked myogenic potentials
timeFrame: up to 6 months
measure: Posturography
timeFrame: up to 6 months
measure: Perception of subjective visual vertical
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Prague
country: Czechia
facility: Department of Rehabilitation and Sports Medicine, University Hospital Motol
Study officials:
References:
Clinical trial NCT03126032: Early Detection of Glycocalyx Damage in Emergency Room Patients
Official title: Early Detection of Glycocalyx Damage in Emergency Room Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
SIRS
Keywords: Sepsis
SIRS
Glycocalyx
Glycocheck™-System
Infection
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
First posted: 2017-04-24
Enrollment: 260
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Non consecutive patients presenting in the ER of the University Hospital in Muenster, Germany.

Brief summary: Aim of the study is to evaluate to what extent a glycocalyx damage measured in the ER in patients presenting with sepsis correlates with their clinical course and if it can be used as a clinical stratification tool and mortality predictor.

The study will focus on the changes of the microcirculation and how they correlate with the macrocirculation, as well as microbiologic parameters. In the study will participate ca. 300 patients with sepsis, as well as 30 patients without sepsis and 30 healthy individuals.


Eligibility criteria: Inclusion Criteria:

Patients with suspected sepsis

* Adult patients presenting to the ER with the clinical suspicion of infection
* Indication for hospital admission

Patients without sepsis

* Adult patients presenting to the ER with other conditions apart from sepsis/infection.

Healthy individuals

* Adult healthy individuals.

Exclusion Criteria (for all groups):

* Underage persons
* Pregnant women
* Oral mucosal injuries

Primary outcomes:
measure: Correlation of glycocalyx thickness with clinical course.
timeFrame: At time of presentation in the ER.
Secondary outcomes:
measure: Correlation of glycocalyx thickness with major events.
timeFrame: Hospital stay, an expected average of 4 weeks.
measure: Correlation of glycocalyx thickness with 90-day mortality.
timeFrame: Up to 90 days.
measure: Correlation of glycocalyx thickness with subsequent organ failure.
timeFrame: Hospital stay, an expected average of 4 weeks.
Other outcomes:
Locations:
city: Muenster
country: Germany
facility: Universitiy Hospital Muenster
Study officials:
affiliation: University Muenster
name: Philipp Kümpers, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06994832: Using Visual Arrays to Support Understanding of Genetic Risk
Official title: Examining Genetic Literacy and Numeracy in the General Population
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Decision Aid
Keywords: Lynch syndrome
colorectal cancer
colon cancer
genetic testing
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
name: Boston College
First posted: 2025-05-29
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: One-to-one randomization into two parallel groups
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims to answer are:

1. Which visual aid most accurately show genetic risk?
2. How do people perceive risk related to genetic test results?
3. What factors are associated with people discussing their results with family?

Participants will:

1. receive of of two visual aids showing risk
2. state their estimation of risk
3. answer questions about how they feel about risk and sharing information with family

Detailed description: This study aims to determine what visual aid helps people most accurately interpret risk from genetic test results. The study also examines how people perceive risk using the Tripartite Risk Model. Last, the study examines factors that are associated with intention to share genetic test results with family members.

Participants will provide brief sociodemographic information, complete brief health literacy and numeracy assessments, and questions about how they perceive risk. Participants will be informed of a genetic testing scenario and will receive one of two visual aids. After reviewing the visual aid, participants will state the risk shown in the visual aid and will answer questions about their perceived risk and sharing results with family members (blood relatives).

Eligibility criteria: Inclusion Criteria:

* ability to read and understand English
* opt-in consent

Exclusion Criteria:

* incorrect responses to validation questions

Primary outcomes:
measure: Risk Accuracy
timeFrame: immediately after the intervention
Secondary outcomes:
measure: Risk Perceptions
timeFrame: baseline
measure: Communication Intent
timeFrame: immediately after the intervention
Other outcomes:
Locations:
Study officials:
affiliation: Boston College
name: Andrew A Dwyer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00826332: Transvaginal vs Transabdominal Ultrasound Guided Embryo Transfer
Official title: Transvaginal or Transabdominal Ultrasound Guided Embryo Transfer- Which is Better?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: In Vitro Fertilization
Keywords: ultrasound
IVF
Embryo transfer
Pregnancy rate
female patient undergoing IVF
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2009-01-22
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Embryo transfer is the last step in the IVF process. it is now recognized that this step should be done carefully and that it affects success rates. in recent years, sonographic guidance appears to increase success rates.

Detailed description: Embryo transfer is the last step in the IVF process. it involves the insertion of a soft catheter through the uterine cervix. It is now recognized that this step should be done carefully and that it affects success rates. The embyos should be carefully deposited in the cavity. special care should be given to avoid touching the uterine fundus during the procedure. In recent years, sonographic guidance appears to increase success rates.

Eligibility criteria: Inclusion Criteria:

* high quality embryos fro transfer

Exclusion Criteria:

* repeated IVF failure

Primary outcomes:
measure: pregnancy
timeFrame: 14 days
Secondary outcomes:
measure: patient satisfaction
timeFrame: 5 minutes
Other outcomes:
Locations:
city: Jerusalem,
country: Israel
facility: Hadassah University Hospital
Study officials:
References:
citation: Sallam HN, Sadek SS. Ultrasound-guided embryo transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 2003 Oct;80(4):1042-6. doi: 10.1016/s0015-0282(03)01009-4.
citation: Karavani G, Ben-Meir A, Shufaro Y, Hyman JH, Revel A. Transvaginal ultrasound to guide embryo transfer: a randomized controlled trial. Fertil Steril. 2017 May;107(5):1159-1165. doi: 10.1016/j.fertnstert.2017.01.023. Epub 2017 Mar 24.
Clinical trial NCT04325932: Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis
Official title: Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis: a Study Based on Whole-brain CTP
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Intracranial Arteriosclerosis
Collateral Circulation
Anterior Cerebral Circulation Infarction
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2020-03-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether Urinary Kallikrein has an additional effect on enhancing collateral circulation in symptomatic intracranial atherosclerotic patients under clopidogrel and aspirin dual antiplatelet therapy.


Eligibility criteria: Inclusion Criteria:

1. Acute ischemic stroke or TIA within 72 hours;
2. Intracranial ICA, MCA M1 segment stenosis (\>70%)

Exclusion Criteria:

1. \>70% Stenosis in an intracranial artery other than the culprit artery.
2. \>50% Stenosis of an extracranial carotid or vertebral artery on the ipsilateral side.
3. Perforator strokes based on MRI.
4. Non-atherosclerotic lesion, for example, moyamoya disease, vascular inflammatory disease due to infection, autoimmunity diseases, developmental or genetic abnormalities, for example, fibromuscular dysplasia, sickle-cell anaemia, suspected vasospasm.
5. Potential cardiac embolism as cause.
6. Intracranial haemorrhage within 6 weeks.
7. Concomitant intracranial tumour, aneurysm or arteriovenous malformation.
8. Known contraindications for heparin, aspirin, clopidogrel or contrast.
9. Haemoglobin \<10 g/dL, blood platelet count \<100 000, international normalisation ratio \>1.5, or other uncorrectable coagulopathies.Impaired liver function (alanine aminotransferase or glutamic oxalacetic transaminase ≥ 3×upper limit of normal) or renal function (serum creatinie ≥ 1.5mg/dl);
10. A baseline modified Rankin Score of ≥3.
11. Life expectancy of \<1 year due to the concomitant illness.
12. Pregnant or lactating women.
13. long-term statins users.
14. History of mental instability or dementia.

Primary outcomes:
measure: the percentage of patients with modified Rankin Score (mRS) equivalent to or less than 2
timeFrame: 3 months
Secondary outcomes:
measure: rLMC scale of Collateral circulation
timeFrame: 2 weeks, 1 month
measure: NIHSS score
timeFrame: 2 weeks, 1month
measure: Hemorrhageic complications
timeFrame: 2 weeks, 1 month, 3 months, 6 months
measure: New stroke or transient ischemic attack(TIA)
timeFrame: 6 months
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The second affiliated hospital of Zhejiang University
state: Zhejiang
Study officials:
affiliation: second affiliated hospital of Zhejiang University, school of medicine
name: Min Lou, Ph.D,M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT04441632: Effect of Positive Attitudes on Behavior and Wellness
Official title: The Impact of Positive Reinforcement on Teamwork Climate, Resiliency, and Burnout During the COVID-19 Pandemic: the TEAM-ICU Study (Transforming Employee Attitudes Via Messaging Strengthens Interconnection, Communication, and Unity)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burnout
Stress, Emotional
Keywords: wellness
healthcare
burnout
COVID
Lead sponsor: Cedars-Sinai Medical Center
Sponsor class: OTHER
First posted: 2020-06-22
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The COVID-19 pandemic has undoubtedly elevated levels of stress to people all over the globe, but none more than to the providers on the front-line. The purpose of the study is to first, assess the effects of the pandemic on burnout, team cohesion, and resiliency among healthcare providers battling COVID-19 together in a medical ICU (MICU). Secondly, the investigators hope to then assess the effects of simple positive feedback on transforming culture and attitudes during times of major stress.


Eligibility criteria: Inclusion Criteria:

* Front-line healthcare providers in the Medical Intensive Care Unit (MICU): nurses, respiratory therapists, resident physicians, fellow physicians, and attending physicians

Exclusion Criteria:

* Healthcare providers providing only consultatory care in the MICU
* Front-line healthcare providers not working in the MICU during the study period

Primary outcomes:
measure: Teamwork climate, as measured by selected items from the validated Safety Attitude Questionnaire (SAQ)
timeFrame: 4 weeks
measure: Resiliency, as measured by the validated Brief Resilience Scale (BRS)
timeFrame: 4 weeks
measure: Burnout, as validated by the single-item burnout scale inventory
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
Study officials:
affiliation: Cedars-Sinai Medical Center
name: Jack Green, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01351532: Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention
Official title: Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oral Cancer
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2011-05-11
Enrollment: 67
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to apply this smoking cessation program on oral cancer patients, and to analyze the effectiveness of it.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of oral cancer
* current smoker

Primary outcomes:
measure: Smoking cessation
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Hospital
Study officials:
References:
Clinical trial NCT04279132: EFFECT OF ANESTHESİA TECHNIQUES ON POSTOPERATİVE COGNİTİVE DYSFUNCTION FOR MMSE AND NSE LEVEL
Official title: THE EFFECT OF TOTAL INTRAVENOUS ANESTHESIA AND INHALATION ANESTHESIA TECHNIQUES FOR MINI MENTAL STATE EXAMINATION TEST AND NEURON SPECIFIC ENOLASE LEVEL IN LUMBAR DISK HERNIECTOMY OPERATIONS
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Postoperative Cognitive Dysfunction
NEURON SPECIFIC ENOLASE
MINI MENTAL STATE EXAMINATION TEST
Lead sponsor: Erzincan University
Sponsor class: OTHER
First posted: 2020-02-20
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lumbal disc herniectomy operation is planned for ASA I, II and III risk group between the ages of 18-65.

Brief summary: The aim of this study is to compare the effects of total intravenous anesthesia and inhalation anesthesia methods on postoperative cognitive dysfunction according to Mini Mental State Examination scores and Neuron Specific Enolase levels in lumbar disc herniectomy operations.


Eligibility criteria: Inclusion Criteria:

-Lumbal disc herniectomy operation 18-65 age

Exclusion Criteria:

* Patients before and after the coronary artery bypass graft surgery
* patients in the last trimester of pregnancy
* patients with severe heart failure
* liver failure
* kidney failure
* malignant hyperthermia
* lactating patients
* patients with vision or hearing problems
* patients having difficulty in understanding and speaking Turkish
* Parkinson's and Alzheimer's disease
* alcohol and drug addicts
* morbidly obese patients
* intraoperative hypotension, hypertension and hypoxemia

Primary outcomes:
measure: MINI MENTAL STATE EXAMINATION TEST
timeFrame: 1 MONTH
Secondary outcomes:
Other outcomes:
Locations:
city: Erzincan
country: Turkey
facility: Erzincan Byu
Study officials:
affiliation: ERZINCAN BYU
name: TÜLAY CEREN ÖLMEZTÜRK KARAKURT
role: PRINCIPAL_INVESTIGATOR
References:
citation: Goswami U, Babbar S, Tiwari S. Comparative evaluation of the effects of propofol and sevoflurane on cognitive function and memory in patients undergoing laparoscopic cholecystectomy: A randomised prospective study. Indian J Anaesth. 2015 Mar;59(3):150-5. doi: 10.4103/0019-5049.153036.
citation: Luescher T, Mueller J, Isenschmid C, Kalt J, Rasiah R, Tondorf T, Gamp M, Becker C, Sutter R, Tisljar K, Schuetz P, Marsch S, Hunziker S. Neuron-specific enolase (NSE) improves clinical risk scores for prediction of neurological outcome and death in cardiac arrest patients: Results from a prospective trial. Resuscitation. 2019 Sep;142:50-60. doi: 10.1016/j.resuscitation.2019.07.003. Epub 2019 Jul 12.
citation: Baysalman HB, Oğuz G, Açıkgöz G, Aksakal FN, Ünver SJJotTA, Dergisi ICS-JTAvR. Total İntravenöz ve Desfluran Anestezilerinin Erken Derlenme ve Kognitif Fonksiyonlara Etkileri. 2011;39(1).
Clinical trial NCT00646932: Paricalcitol Injection Phase II Trial
Official title: A Phase 2, Open-Label, Multicenter, Multi-Dose Study to Evaluate the Pharmacokinetics and Tolerability of Paricalcitol Injection in Chronic Kidney Disease Stage 5 Subjects With Secondary Hyperparathyroidism Undergoing Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Kidney Disease
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2008-03-31
Enrollment: 25
Sex: ALL
Minimum age (years): 20
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure.

Detailed description: The purpose of this study is pharmacokinetic \& tolerability.

Eligibility criteria: Inclusion Criteria:

* Subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure

Exclusion Criteria:

* Subject is considered by investigator, for any reason, to be an unsuitable candidate for the study

Primary outcomes:
measure: Pharmacokinetics
timeFrame: 2 weeks
Secondary outcomes:
measure: Safety
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Gunma
country: Japan
city: Hokkaido
country: Japan
city: Ibaraki
country: Japan
city: Kagoshima
country: Japan
city: Kumamoto
country: Japan
city: Nagano
country: Japan
city: Nagasaki
country: Japan
city: Saitama
country: Japan
city: Shizuoka
country: Japan
city: Tokyo
country: Japan
Study officials:
affiliation: Abbott
name: Hideaki Harada
role: STUDY_DIRECTOR
References: